$Tiziana Life Sciences(TLSA.US)$Tiziana Life Sciences: Files for Orphan Drug Designation for Intranasal Foralumab to Treat Non-Active Secondary Progressive Multiple Sclerosis
$Tiziana Life Sciences(TLSA.US)$ NEWS Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab Tiziana Life Sciences, a biotechnology company, files for Orphan Drug Designation for intranasal foralumab for treating non-active secondary progressive Multiple Sclerosis, aiming to be the first therapy to receive this designation. Supported by clinical evidence, the drug has shown positive results in an Expanded Access Program, improving fatigue in 70% of patients. A Phase 2a ...
$Tiziana Life Sciences(TLSA.US)$Tiziana Life Sciences Announces FDA Allowance for Additional Twenty Patients to Be Enrolled in the Intranasal Foralumab Multiple Sclerosis Expanded Access Program
$Tiziana Life Sciences(TLSA.US)$Tiziana Life Sciences Says Study Results From Intranasal Anti-CD3 Foralumab In Multiple Sclerosis Patients With PIRA Highlighted In Neurology Today! Says that treatment shows potential
$Tiziana Life Sciences(TLSA.US)$ NEWS Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology Tiziana Life Sciences (TLSA) announces an upcoming oral presentation on the treatment of PIRA with Nasal Foralumab for Multiple Sclerosis at the AAN Annual Meeting. Presenter is Tarun Singhal from Harvard Medical School. The presentation aims to dampen microglial activation and stabilize clinical p...
$Tiziana Life Sciences(TLSA.US)$Tiziana Life Sciences To Present Data Of Intranasal Anti-CD3 Monoclonal Antibody In Alzheimer's And Parkinson's Models On Mar. 8
Tiziana Life Sciences股票讨论区
NEWS
Tiziana Life Sciences Files for Orphan Drug Designation for Intranasal Foralumab
Tiziana Life Sciences, a biotechnology company, files for Orphan Drug Designation for intranasal foralumab for treating non-active secondary progressive Multiple Sclerosis, aiming to be the first therapy to receive this designation. Supported by clinical evidence, the drug has shown positive results in an Expanded Access Program, improving fatigue in 70% of patients. A Phase 2a ...
NEWS
Tiziana Life Sciences Announces Platform Presentation of New Quantitative PET Imaging Data on Foralumab at the Annual Meeting of the American Academy of Neurology
Tiziana Life Sciences (TLSA) announces an upcoming oral presentation on the treatment of PIRA with Nasal Foralumab for Multiple Sclerosis at the AAN Annual Meeting. Presenter is Tarun Singhal from Harvard Medical School. The presentation aims to dampen microglial activation and stabilize clinical p...
暂无评论